Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact
January 11, 2012
Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genentech Partners with Xenon to Discover, Develop Genetically Targeted Pain Drugs, Companion Tests
January 11, 2012 / Pharmacogenomics Reporter - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Roche Gets EC Nod for Tarceva as First-Line Therapy in EGFR-mutated NSCLC; Awaits CE Mark for CDx
September 7, 2011 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter